Investigational Drug Information for Famitinib
✉ Email this page to a colleague
What is the drug development status for Famitinib?
Famitinib is an investigational drug.
There have been 48 clinical trials for Famitinib.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 12th 2020.
The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Sun Yat-sen University.
There are twenty-five US patents protecting this investigational drug and three hundred and eighty international patents.
Summary for Famitinib
| US Patents | 25 |
| International Patents | 380 |
| US Patent Applications | 110 |
| WIPO Patent Applications | 102 |
| Japanese Patent Applications | 41 |
| Clinical Trial Progress | Phase 3 (2020-09-12) |
| Vendors | 18 |
Recent Clinical Trials for Famitinib
| Title | Sponsor | Phase |
|---|---|---|
| PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer | Fudan University | Phase 3 |
| Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | Fudan University | Phase 2 |
| A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC. | Fudan University | Phase 2 |
Clinical Trial Summary for Famitinib
Top disease conditions for Famitinib
Top clinical trial sponsors for Famitinib
US Patents for Famitinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Famitinib | ⤷ Subscribe | Substituted urea derivatives and pharmaceutical uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN) | ⤷ Subscribe |
| Famitinib | ⤷ Subscribe | Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis | Genentech, Inc. (South San Francisco, CA) | ⤷ Subscribe |
| Famitinib | ⤷ Subscribe | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Subscribe |
| Famitinib | ⤷ Subscribe | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Subscribe |
| Famitinib | ⤷ Subscribe | Methods of treatment of malignancies | Celgene Corporation (Summit, NJ) Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Subscribe |
| Famitinib | ⤷ Subscribe | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Subscribe |
| Famitinib | ⤷ Subscribe | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Famitinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Famitinib | Australia | AU2015291522 | 2034-07-17 | ⤷ Subscribe |
| Famitinib | Canada | CA2952083 | 2034-07-17 | ⤷ Subscribe |
| Famitinib | China | CN105272930 | 2034-07-17 | ⤷ Subscribe |
| Famitinib | Denmark | DK3169671 | 2034-07-17 | ⤷ Subscribe |
| Famitinib | European Patent Office | EP3169671 | 2034-07-17 | ⤷ Subscribe |
| Famitinib | Spain | ES2747249 | 2034-07-17 | ⤷ Subscribe |
| Famitinib | Hong Kong | HK1232224 | 2034-07-17 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
